BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

133 related articles for article (PubMed ID: 38364701)

  • 21. TP53 or CDKN2A/B covariation in ALK/RET/ROS1-rearranged NSCLC is associated with a high TMB, tumor immunosuppressive microenvironment and poor prognosis.
    Jiang B; Hu L; Dong D; Guo Z; Wei W; Wang C; Shao W; Ma T; Chen Y; Li Q; Hu W
    J Cancer Res Clin Oncol; 2023 Sep; 149(12):10041-10052. PubMed ID: 37261522
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Genomic landscape and its correlations with tumor mutational burden, PD-L1 expression, and immune cells infiltration in Chinese lung squamous cell carcinoma.
    Jiang T; Shi J; Dong Z; Hou L; Zhao C; Li X; Mao B; Zhu W; Guo X; Zhang H; He J; Chen X; Su C; Ren S; Wu C; Zhou C
    J Hematol Oncol; 2019 Jul; 12(1):75. PubMed ID: 31299995
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The Unique Genetic Mutation Characteristics Based on Large Panel Next-Generation Sequencing (NGS) Detection in Multiple Primary Lung Cancers (MPLC) Patients.
    Liang Z; Zeng G; Wan W; Deng B; Chen C; Li F; Lin G; Lin Y; Lin H; Mo G; Miao H
    Discov Med; 2023 Apr; 35(175):131-143. PubMed ID: 37188510
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Characteristics of the immune microenvironment and their clinical significance in non-small cell lung cancer patients with ALK-rearranged mutation.
    Zhang B; Zeng J; Zhang H; Zhu S; Wang H; He J; Yang L; Zhou N; Zu L; Xu X; Song Z; Xu S
    Front Immunol; 2022; 13():974581. PubMed ID: 36159860
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Research Progress in Distinguishing Methods of Simultaneous Multiple Primary Lung Cancer and Intrapulmonary Metastasis].
    Wang J; Zhang T; Ding H; Dong G; Xu L; Jiang F
    Zhongguo Fei Ai Za Zhi; 2021 May; 24(5):365-371. PubMed ID: 34034461
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Clonal expansion of shared T cell receptors reveals the existence of immune commonality among different lesions of synchronous multiple primary lung cancer.
    Wang Y; Huang Z; Li B; Xue J; Guo C; Bing Z; Zheng Z; Song Y; Xu Y; Huang G; Li H; Yu X; Xia Y; Li R; Si X; Zhang L; Li J; Song L; Xiong Y; Gu D; Song M; Zhou Z; Chen R; Feng Z; Bie Z; Li X; Yang H; Li S; Liang N
    Cancer Immunol Immunother; 2024 Apr; 73(6):111. PubMed ID: 38668781
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Lineage tracing for multiple lung cancer by spatiotemporal heterogeneity using a multi-omics analysis method integrating genomic, transcriptomic, and immune-related features.
    Song Y; Zhou J; Zhao X; Zhang Y; Xu X; Zhang D; Pang J; Bao H; Ji Y; Zhan M; Wang Y; Ou Q; Hu J
    Front Oncol; 2023; 13():1237308. PubMed ID: 37799479
    [TBL] [Abstract][Full Text] [Related]  

  • 28. KRAS-G12D mutation drives immune suppression and the primary resistance of anti-PD-1/PD-L1 immunotherapy in non-small cell lung cancer.
    Liu C; Zheng S; Wang Z; Wang S; Wang X; Yang L; Xu H; Cao Z; Feng X; Xue Q; Wang Y; Sun N; He J
    Cancer Commun (Lond); 2022 Sep; 42(9):828-847. PubMed ID: 35811500
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Next-generation sequencing facilitates differentiating between multiple primary lung cancer and intrapulmonary metastasis: a case series.
    Liu C; Liu C; Zou X; Shao L; Sun Y; Guo Y
    Diagn Pathol; 2021 Mar; 16(1):21. PubMed ID: 33706781
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Elucidation of the relationships of MET protein expression and gene copy number status with PD-L1 expression and the immune microenvironment in non-small cell lung cancer.
    Yoshimura K; Inoue Y; Tsuchiya K; Karayama M; Yamada H; Iwashita Y; Kawase A; Tanahashi M; Ogawa H; Inui N; Funai K; Shinmura K; Niwa H; Suda T; Sugimura H
    Lung Cancer; 2020 Mar; 141():21-31. PubMed ID: 31931443
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Lack of evolutionary convergence in multiple primary lung cancer suggests insufficient specificity of personalized therapy.
    Cheng H; Guo Z; Zhang X; Wang XJ; Li Z; Huo WW; Zhong HC; Li XJ; Wu XW; Li WH; Chen ZW; Wu TC; Gan XF; Zhong BL; Lyubetsky VA; Rusin LY; Yang J; Zhao Q; Cao QD; Yang JR
    J Genet Genomics; 2023 May; 50(5):330-340. PubMed ID: 36414223
    [TBL] [Abstract][Full Text] [Related]  

  • 32. B7-1 and programmed cell death-ligand 1 in primary and lymph node metastasis lesions of non-small cell lung carcinoma.
    Yamada T; Miki Y; Suzuki M; Kondoh O; Saito-Koyama R; Ono K; Okada Y; Sasano H
    Cancer Med; 2022 Jan; 11(2):479-491. PubMed ID: 34907653
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Molecular Identification and Genetic Characterization of Early-Stage Multiple Primary Lung Cancer by Large-Panel Next-Generation Sequencing Analysis.
    Pei G; Li M; Min X; Liu Q; Li D; Yang Y; Wang S; Wang X; Wang H; Cheng H; Cao S; Huang Y
    Front Oncol; 2021; 11():653988. PubMed ID: 34109114
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Multidimensional profiling depicts infiltrating immune cell heterogeneity in the tumor microenvironment of stage IA non-small cell lung cancer.
    Duan J; Lv G; Zhu N; Chen X; Shao Y; Liu Y; Zhao W; Shi Y
    Thorac Cancer; 2022 Apr; 13(7):947-955. PubMed ID: 35150094
    [TBL] [Abstract][Full Text] [Related]  

  • 35. PD-L1 expression and T cells infiltration in patients with uncommon EGFR-mutant non-small cell lung cancer and the response to immunotherapy.
    Chen K; Cheng G; Zhang F; Zhu G; Xu Y; Yu X; Huang Z; Fan Y
    Lung Cancer; 2020 Apr; 142():98-105. PubMed ID: 32120230
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Landscape of Genomic Alterations and PD-L1 Expression in Early-Stage Non-Small-Cell Lung Cancer (NSCLC)-A Single Center, Retrospective Observational Study.
    Stephan-Falkenau S; Streubel A; Mairinger T; Kollmeier J; Misch D; Thiel S; Bauer T; Pfannschmidt J; Hollmann M; Wessolly M; Blum TG
    Int J Mol Sci; 2022 Oct; 23(20):. PubMed ID: 36293366
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Tumor immune microenvironment and nivolumab efficacy in EGFR mutation-positive non-small-cell lung cancer based on T790M status after disease progression during EGFR-TKI treatment.
    Haratani K; Hayashi H; Tanaka T; Kaneda H; Togashi Y; Sakai K; Hayashi K; Tomida S; Chiba Y; Yonesaka K; Nonagase Y; Takahama T; Tanizaki J; Tanaka K; Yoshida T; Tanimura K; Takeda M; Yoshioka H; Ishida T; Mitsudomi T; Nishio K; Nakagawa K
    Ann Oncol; 2017 Jul; 28(7):1532-1539. PubMed ID: 28407039
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Diagnosis of multiple primary lung cancer: a systematic review.
    Xue X; Liu Y; Pan L; Wang Y; Wang K; Zhang M; Wang P; Wang J
    J Int Med Res; 2013 Dec; 41(6):1779-87. PubMed ID: 24265329
    [TBL] [Abstract][Full Text] [Related]  

  • 39. ILT4 inhibition prevents TAM- and dysfunctional T cell-mediated immunosuppression and enhances the efficacy of anti-PD-L1 therapy in NSCLC with EGFR activation.
    Chen X; Gao A; Zhang F; Yang Z; Wang S; Fang Y; Li J; Wang J; Shi W; Wang L; Zheng Y; Sun Y
    Theranostics; 2021; 11(7):3392-3416. PubMed ID: 33537094
    [No Abstract]   [Full Text] [Related]  

  • 40. [Correlation between Immune Microenvironment Features and EGFR Mutation Status 
in Lung Adenocarcinoma].
    Zhu H; Chen P; Dong G; Meng F; Xia Z; You J; Kong X; Wu J; Yuan F; Yu X; Sun Q; Ji J; Wang S; Liu T; Xu L
    Zhongguo Fei Ai Za Zhi; 2023 Mar; 26(3):204-216. PubMed ID: 37035883
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.